Cited by 1,145Schizophrenia research and treatmentPharmacology and Obesity TreatmentHIV-related health complications and treatments

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index.

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology

DOI 10.1038/nrendo.2011.156

Open this paper in CoChat — free account

Abstract

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease. Controversy remains about the contribution of individual antipsychotic drugs to this increased risk and whether they cause sudden cardiac death through prolongation of the corrected QT interval. Although some drug receptor-binding affinities correlate with specific cardiovascular and metabolic abnormalities, the exact pharmacological mechanisms underlying these associations remain unclear. Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both obesity-related and obesity-unrelated molecular mechanisms. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not assessed for even the most easily measurable metabolic and cardiac risk factors, such as obesity and blood pressure. Subsequently, concerns have been raised over the use of these medications, especially pronounced in vulnerable pediatric patients, among whom their use has increased markedly in the past decade and seems to have especially orexigenic effects. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and finally makes recommendations for screening and monitoring of patients taking these agents.

Integrity signals

Registry

Crossref · 10.1038/nrendo.2011.156

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Bipolar Disorder
Yatham, L. N., & Malhi, G. S. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,515
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Systematic review and meta-analysis
Gillies, A. (2019) · CRC Press eBooks · doi:10.1201/9781315377315-19 · Cited by 2,876
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
A Population-Based Study
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,290
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Myerburg, R. J., Quiñones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,975

Flagged first, then by citations

Show all 131 references

1 of the 131 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Citrome, L. Risk–benefit analysis of available treatments for schizophrenia. Psychiatric Times 1, 27–30 (2007).

Sorted by citations

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: A large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa‐Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., et al. (2017) · World Psychiatry · doi:10.1002/wps.20420 · Cited by 1,729
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015) · World Psychiatry · doi:10.1002/wps.20252 · Cited by 1,271
Self-citation
Schizophrenia
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer‐Lindenberg, A., Weinberger, D. R., Cannon, T. D., O’Donovan, M. C., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,163
A review of depression and suicide risk assessment using speech analysis
Cummins, N., Scherer, S. J., Krajewski, J., Schnieder, S., Epps, J., & Quatieri, T. F. (2015) · Speech Communication · doi:10.1016/j.specom.2015.03.004 · Cited by 1,051
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P. A. P. M., Taipale, H. T., et al. (2022) · World Psychiatry · doi:10.1002/wps.20994 · Cited by 758
Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta‐analysis
Vancampfort, D., Correll, C. U., Galling, B., Probst, M., De Hert, M., Ward, P. B., Rosenbaum, S., Gaughran, F., Lally, J., & Stubbs, B. (2016) · World Psychiatry · doi:10.1002/wps.20309 · Cited by 659
Automated assessment of psychiatric disorders using speech: A systematic review
Low, D. M., Bentley, K. H., & Ghosh, S. (2020) · Laryngoscope Investigative Otolaryngology · doi:10.1002/lio2.354 · Cited by 545
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“Indeed some reviews address this issue although restricted to only schizophrenia and bipolar disorder [27,61].”
Background
Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators
Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., Herdt, A. D., Sienaert, P. A., Probst, M., & Binder, M. D. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050620 · Cited by 462
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Thibaut, F., Möller, H., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 424
Cardiovascular disease in patients with severe mental illness
Nielsen, R. E., Banner, J., & Jensen, S. E. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00463-7 · Cited by 389
20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1314 · Cited by 384
The WPA-Lancet psychiatry commission on the future of psychiatry
Bhugra, D., Tasman, A., Pathare, S., Priebe, S., Smith, S., Torous, J., Arbuckle, M. R., Langford, A., Alarcón, R. D., Chiu, H. F. K., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30333-4 · Cited by 392
Antipsychotic-associated weight gain: management strategies and impact on treatment adherence
Dayabandara, M., Hanwella, R., Ratnatunga, S. S., Seneviratne, S., Suraweera, C. U., & de Silva, V. A. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s113099 · Cited by 399
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis
Zhang, J., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 347
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients
Mitchell, A. J., Vancampfort, D., Herdt, A. D., Yu, W., & Hert, M. D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs082 · Cited by 347
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
Kane, J. M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.038 · Cited by 325
A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls
Vancampfort, D., Wampers, M., Mitchell, A. J., Correll, C. U., Herdt, A. D., Probst, M., & Binder, M. D. (2013) · World Psychiatry · doi:10.1002/wps.20069 · Cited by 335
Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics
Masuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 321
Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables
Vancampfort, D., Correll, C. U., Wampers, M., Sienaert, P., Mitchell, A. J., De Herdt, A., Probst, M., Scheewe, T. W., & De Hert, M. (2014) · Psychological Medicine · doi:10.1017/s0033291713002778 · Cited by 317
Self-citation
High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice
Arnold, S. E., Lucki, I., Brookshire, B. R., Carlson, G. C., Browne, C. A., Kazi, H., Bang, S., Choi, B., Chen, Y., McMullen, M. F., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.011 · Cited by 320
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia
Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S. L., & Vanover, K. E. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4379 · Cited by 289
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
Manu, P., Dima, L., Shulman, M., Vancampfort, D., Hert, M. A. F. D., & Correll, C. U. (2015) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12445 · Cited by 302
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Lieberman, J. A., Davis, R. E., Correll, C. U., GOFF, D. C., Kane, J. M., Tamminga, C. A., Mates, S. L., & Vanover, K. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.026 · Cited by 263
Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010
Ilyas, S., & Moncrieff, J. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.104257 · Cited by 262
Physical activity, exercise, and mental disorders: it is time to move on
Schuch, F. B., & Vancampfort, D. (2021) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2021-0237 · Cited by 251
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial
Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250
Self-citation
Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?
Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244
Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1–12.5 Years
Vermeulen, J. M., van Rooijen, G., van de Kerkhof, M. P. J., Sutterland, A. L., Correll, C. U., & de Haan, L. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby052 · Cited by 246
Self-citation
A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders
Sendt, K.-V., Tracy, D. K., & Bhattacharyya, S. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.002 · Cited by 245
Obesity and Autism
Hill, A. P., Zuckerman, K. E., & Fombonne, E. J. (2015) · PEDIATRICS · doi:10.1542/peds.2015-1437 · Cited by 256
Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta‐analysis and meta‐regression analysis
Galling, B., Roldán, A., Hagi, K., Rietschel, L., Walyzada, F., Zheng, W., Cao, X., Xiang, Y., Zink, M., Kane, J. M., et al. (2017) · World Psychiatry · doi:10.1002/wps.20387 · Cited by 253
Termination of Clozapine Treatment Due to Medical Reasons
Nielsen, J., Correll, C. U., Manu, P., & Kane, J. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08064 · Cited by 232
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
Galling, B., Roldán, A., Nielsen, R. E., Nielsen, J., Gerhard, T., Carbon, M., Stubbs, B., Vancampfort, D., Binder, M. D., Olfson, M., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2923 · Cited by 229
Inflammatory cytokines and anorexia nervosa: A meta-analysis of cross-sectional and longitudinal studies
Solmi, M., Veronese, N., Favaro, A., Santonastaso, P., Manzato, E., Sergi, G., & Correll, C. U. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.031 · Cited by 222
Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology
Rojo, L. E., Gaspar, P. A., Silva, H., Risco, L., Arena, P., Cubillos-Robles, K., & Jara, B. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.022 · Cited by 219
The interface of physical and mental health
Doherty, A. M., & Gaughran, F. (2014) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-014-0847-7 · Cited by 237
The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial
Green, C. A., Yarborough, B. J. H., Leo, M. C., Yarborough, M. T., Stumbo, S. P., Janoff, S. L., Perrin, N., Nichols, G. A., & Stevens, V. J. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020173 · Cited by 223
Safety and tolerability of antipsychotic polypharmacy
Gallego, J. A., Nielsen, J., Binder, M. D., Kane, J. M., & Correll, C. U. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.683523 · Cited by 207
Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
Mazereel, V., Detraux, J., Vancampfort, D., van Winkel, R., & Binder, M. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573479 · Cited by 233
Antipsychotic Drugs and the Risk of Ventricular Arrhythmia and/or Sudden Cardiac Death: A Nation-wide Case-Crossover Study
Wu, C., Tsai, Y., & Tsai, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001568 · Cited by 191
2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee
Bueno, H., Deaton, C., Farrero, M., Forsyth, F., Braunschweig, F., Buccheri, S., Dragan, S. R., Gevaert, S., Held, C., Kurpas, D., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf191 · Cited by 224
Weight gain and antipsychotics: a drug safety review
Musil, R., Obermeier, M., Russ, P., & Hamerle, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.974549 · Cited by 187
Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects
Siafis, S., Tzachanis, D., Samara, M. T., & Papazisis, G. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170630163616 · Cited by 195
Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010
Charlson, F., Baxter, A. J., Dua, T., Degenhardt, L. J., Whiteford, H., & Vos, T. (2014) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796014000687 · Cited by 194
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
Correll, C. U., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101275 · Cited by 183
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials.
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182
Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis
Zhang, J., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L. A., John, M., Robinson, D. G., Fleischhacker, W. W., Kahn, R. S., Ophoff, R. A., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw058 · Cited by 186
Diabetes mellitus and severe mental illness: mechanisms and clinical implications
Holt, R. I. G., & Mitchell, A. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.203 · Cited by 189
TYPE 2 DIABETES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF PREVALENCE ESTIMATES AND PREDICTORS: Review: Depression and Diabetes
Vancampfort, D., Mitchell, A. J., De Hert, M., Sienaert, P., Probst, M., Buys, R., & Stubbs, B. (2015) · Depression and Anxiety · doi:10.1002/da.22387 · Cited by 171
Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia.
Vancampfort, D., Probst, M., Scheewe, T., De Herdt, A., Sweers, K., Knapen, J., van Winkel, R., & De Hert, M. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.026 · Cited by 173
Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis
Pillinger, T., Beck, K., Stubbs, B., & Howes, O. D. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.117.200907 · Cited by 177
Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia
Hagi, K., Nosaka, T., Dickinson, D., Lindenmayer, J. P., Lee, J., Friedman, J. I., Boyer, L., Han, M., Rashid, N. A. A., & Correll, C. U. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0015 · Cited by 171
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
Loebel, A. D., Cucchiaro, J. B., Sarma, K., Xu, L., Hsu, C., Kalali, A. H., Pikalov, A., & Potkin, S. G. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.009 · Cited by 170
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics
Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 177
Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system
Leung, J. Y. T., Barr, A. M., Procyshyn, R. M., Honer, W. G., & Pang, C. C. Y. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.04.003 · Cited by 163
Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
Binder, M. D., Yu, W., Detraux, J., Sweers, K., van Winkel, R., & Correll, C. U. (2012) · CNS Drugs · doi:10.2165/11634500-000000000-00000 · Cited by 169
Perspectives on Aging and Quality of Life
Noto, S. (2023) · Healthcare · doi:10.3390/healthcare11152131 · Cited by 182
Aerobic Exercise as a Tool to Improve Hippocampal Plasticity and Function in Humans: Practical Implications for Mental Health Treatment
Kandola, A., Hendrikse, J., Lucassen, P. J., & Yücel, M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00373 · Cited by 155
“Both antipsychotic (De Hert et al., 2012) and antidepressant (Anderson et al., 2012) medications are associated with numerous adverse side eﬀects that range from more common and less severe symptoms like headaches or nausea, to less common but more severe symptoms like cardiovascular or metabolic…”
Influential
Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries
Stubbs, B., Koyanagi, A., Veronese, N., Vancampfort, D., Solmi, M., Gaughran, F., Carvalho, A. F., Lally, J., Mitchell, A. J., Mugisha, J., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0734-z · Cited by 151
Effects of Antipsychotic Medications on Appetite, Weight, and Insulin Resistance
Deng, C. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.006 · Cited by 156
Diagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 171
Glucagon‐like peptide‐1 receptor agonists for antipsychotic‐associated cardio‐metabolic risk factors: A systematic review and individual participant data meta‐analysis
Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144
Self-citation
White Matter Changes Associated with Antipsychotic Treatment in First-Episode Psychosis
Szeszko, P. R., Robinson, D. G., Ikuta, T., Peters, B. D., Gallego, J. A., Kane, J. M., & Malhotra, A. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.288 · Cited by 142
Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study
Rajkumar, A. P., Horsdal, H. T., Wimberley, T., Cohen, D., Mors, O., Børglum, A. D., & Gasse, C. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040442 · Cited by 137
Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
Vermeulen, J., van Rooijen, G., Doedens, P., Numminen, E., van Tricht, M., & de Haan, L. (2017) · Psychological Medicine · doi:10.1017/s0033291717000873 · Cited by 134
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review
McGinty, E. E., Baller, J. B., Azrin, S. T., Juliano‐Bult, D., & Daumit, G. L. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv101 · Cited by 139
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors
Pérez‐Iglesias, R., Martínez‐García, O., Pardo‐García, G., Amado, J., García‐Unzueta, M. T., Tabarés‐Seisdedos, R., & Crespo‐Facorro, B. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001053 · Cited by 139
Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial
Croarkin, P. E., Elmaadawi, A. Z., Aaronson, S. T., Schrodt, G. R., Holbert, R. C., Verdoliva, S., Heart, K. L., Demitrack, M. A., & Strawn, J. R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00829-y · Cited by 133
Are Antipsychotics or Antidepressants Needed for Psychotic Depression?: A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy With Combination Treatment
Farahani, A., & Correll, C. U. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07324 · Cited by 131
Self-citation
Molecular pathophysiology of metabolic effects of antipsychotic medications
Ballon, J. S., Pajvani, U. B., Freyberg, Z., Leibel, R. L., & Lieberman, J. A. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.07.004 · Cited by 133
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials
Wu, H., Siafis, S., Hamza, T., Schneider‐Thoma, J., Davis, J. M., Salanti, G., & Leucht, S. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac001 · Cited by 131
Randomized, Double-Blind, Placebo-Controlled Trial Demonstrates the Efficacy and Safety of Oral Aripiprazole for the Treatment of Tourette's Disorder in Children and Adolescents
Sallee, F. R., Kohegyi, E., Zhao, J. L., McQuade, R. D., Cox, K., Sanchez, R., van Beek, A., Nyilas, M., Carson, W. H., & Kurlan, R. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0026 · Cited by 129
Cardiometabolic effects of psychotropic medications
Abosi, O. J., Lopes, S., Schmitz, S. L., & Fiedorowicz, J. G. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0065 · Cited by 135
Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons
Kishimoto, T., Hagi, K., Nitta, M., Kane, J. M., & Correll, C. U. (2019) · World Psychiatry · doi:10.1002/wps.20632 · Cited by 133
The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review
Papanastasiou, E. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312464385 · Cited by 131
The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain
He, M. X., Deng, C., & Huang, X. (2013) · CNS Drugs · doi:10.1007/s40263-013-0062-1 · Cited by 127
Non-alcoholic Fatty Liver Disease (NAFLD) as a Neglected Metabolic Companion of Psychiatric Disorders: Common Pathways and Future Approaches
Soto-Angona, Ó., Anmella, G., Valdés-Florido, M. J., De Uribe-Viloria, N., Carvalho, A. F., Penninx, B. W. J. H., & Berk, M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01713-8 · Cited by 122
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study
Correll, C. U., Newcomer, J. W., Silverman, B. L., DiPetrillo, L., Graham, C. E., Jiang, Y., Du, Y., Simmons, A., Hopkinson, C., McDonnell, D., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19121279 · Cited by 123
Dopaminergic drugs in type 2 diabetes and glucose homeostasis
Vicchi, F. L., Luque, G. M., Brie, B., Nogueira, J. P., Tornadu, I. A. G., & Becú‐Villalobos, D. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.029 · Cited by 118
Mortality gap and physical comorbidity of people with severe mental disorders: the public health scandal
Fiorillo, A., & Sartorius, N. (2021) · Annals of General Psychiatry · doi:10.1186/s12991-021-00374-y · Cited by 117
Osteoporosis and fracture risk in people with schizophrenia
Kishimoto, T., Binder, M. D., Carlson, H. E., Manu, P., & Correll, C. U. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328355e1ac · Cited by 121
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · CNS Spectrums · doi:10.1017/s109285291900124x · Cited by 120
Antidepressants- and antipsychotics-induced hepatotoxicity
Todorović, N., Đorđević, J., Pejić, S., Đorđević, N. O., & Pajović, S. B. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02963-4 · Cited by 121
Classics in Chemical Neuroscience: Aripiprazole
Casey, A. B., & Canal, C. E. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00087 · Cited by 118
Diet and Psychosis: A Scoping Review
Aucoin, M., LaChance, L., Cooley, K., & Kidd, S. A. (2018) · Neuropsychobiology · doi:10.1159/000493399 · Cited by 114
Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-Analysis
Park, S. Y., Cervesi, C., Galling, B., Molteni, S., Walyzada, F., Ameis, S. H., Gerhard, T., Olfson, M., & Correll, C. U. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.03.012 · Cited by 109
Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
Weston–Green, K., Huang, X., & Deng, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0115-5 · Cited by 111
Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials
Burschinski, A., Schneider‐Thoma, J., Chiocchia, V., Schestag, K., Wang, D., Siafis, S., Bighelli, I., Wu, H., Hansen, W., Priller, J., et al. (2023) · World Psychiatry · doi:10.1002/wps.21036 · Cited by 118
Antipsychotic medication for women with schizophrenia spectrum disorders
Brand, B. A., Haveman, Y. R. A., de Beer, F., de Boer, J. N., Dazzan, P., & Sommer, I. E. (2021) · Psychological Medicine · doi:10.1017/s0033291721004591 · Cited by 106
Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management
Peritogiannis, V., Ninou, A., & Samakouri, M. A. (2022) · Healthcare · doi:10.3390/healthcare10122366 · Cited by 104
Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study
Correll, C. U., Joffe, B. I., Rosen, L. M., Sullivan, T. B., & Joffe, R. T. (2015) · World Psychiatry · doi:10.1002/wps.20187 · Cited by 102
The efficacy of meditation-based mind-body interventions for mental disorders: A meta-review of 17 meta-analyses of randomized controlled trials
Vancampfort, D., Stubbs, B., Van Damme, T., Smith, L., Hallgren, M., Schuch, F., Deenik, J., Rosenbaum, S., Ashdown-Franks, G., Mugisha, J., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.048 · Cited by 99
Mindfulness-based cognitive therapy for youth with anxiety disorders at risk for bipolar disorder: a pilot trial
Cotton, S., Luberto, C. M., Sears, R. W., Strawn, J. R., Stahl, L., Wasson, R. S., Blom, T. J., & Delbello, M. P. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12216 · Cited by 96

Authors: De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U.
Affiliations: KU Leuven (BE)
Zucker Hillside Hospital (US)
ORCID: Detraux, Johan
Correll, Christoph U.
Venue: Nature Reviews Endocrinology
Publisher: Springer Science and Business Media LLC
Published: 2011-10-18
Volume: 8
Issue: 2
Pages: 114-126
ISSN: 1759-5029 (ISSN-L)
1759-5037
DOI: 10.1038/nrendo.2011.156
OpenAlex: W2014026290
Cited by: 1,145
References: 131
Citations by year: 2026: 85 · 2025: 75 · 2024: 62 · 2023: 91 · 2022: 97 · 2021: 99 · 2020: 84 · 2019: 77 · 2018: 73 · 2017: 85 · 2016: 74 · 2015: 75 · 2014: 65 · 2013: 52 · 2012: 44
FWCI: 6.96
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Endocrinology (publishedVersion)
PubMed (publishedVersion)
Research Publications (Maastricht University) (submittedVersion)
Lirias (KU Leuven) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: antipsychotic drugs, type 2 diabetes, cardiovascular disease, metabolic side effects, obesity, hyperglycemia, dyslipidemia, metabolic syndrome, QT prolongation, sudden cardiac death, glucose metabolism, lipid metabolism, health care disparities, screening and monitoring
MeSH terms: Adult, Cardiovascular Diseases, Child, Diabetes Mellitus, Humans, Metabolic Diseases, Antipsychotic Agents, Weight Gain, Death, Sudden, Cardiac

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks